After having been diagnosed with myeloma in 2019, Vincent Claus got in touch with MPE and joined the Taskforce. In 2022, he joined the Advocate Development Programme (ADP) and has since then been involved in many patient advocacy efforts such as SISAQOL-IMI. Recently with the support of MPE, he launched a specific support group for younger myeloma patients (European Young Myeloma Patients Group). His main fields of interest are the youngest myeloma population, lobbying for early(er) diagnosis and equal treatment approaches across Europe.
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and Wales
After the approval of the first bispecific antibody for myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom’s public body for medicine appraisals) approved…